COATESVILLE, PA — Pression is more than doubling its Coatesville footprint as the medical-device startup moves its Wave PRO external counterpulsation system into manufacturing and sales following federal clearance, shifting the company from product development toward commercial operations.
The company has added about 3,000 square feet at its 190 West Lincoln Highway facility, where it plans to conduct final assembly, testing, and distribution of the portable cardiac-therapy system.
Most components come from suppliers within roughly 90 minutes of Pression’s headquarters, including machining performed in Honey Brook, keeping a significant portion of the device’s supply chain close to its Coatesville operations.
Pression currently has four full-time employees and works with a broader group of about 20 consultants and collaborators.
The first Wave PRO unit is now in the field with the company’s sales team. Management hopes to record its first commercial sales within the next several months as it introduces the system to cardiologists and health-care facilities.
The commercialization follows U.S. Food and Drug Administration 510(k) clearance received in December 2025. The clearance allows Pression to market Wave PRO in the U.S. for specified uses, including treatment of chronic stable angina that is refractory to optimal anti-anginal medical therapy in adult patients without options for revascularization and weighing more than 40 kilograms.
Wave PRO uses inflatable sleeves around a patient’s calves to apply pressure synchronized with the cardiac cycle. Five bladders inflate sequentially from the ankles toward the knees during diastole, when the heart is relaxed, to increase retrograde aortic flow and enhance coronary perfusion.
The system is intended for use under the supervision of a health-care professional.
Pression is positioning portability and operating requirements as key distinctions for Wave PRO. The device is designed as an alternative to conventional external counterpulsation equipment that can weigh about 700 pounds and require dedicated treatment rooms.
The company says Wave PRO requires minimal setup and can operate autonomously once treatment is initiated, allowing it to fit within existing staffing models and a broader range of care settings. Pression is targeting cardiologists, outpatient providers, and cardiac rehabilitation programs as it begins commercialization.
The smaller system could also broaden where external counterpulsation therapy can be offered, including rural hospitals and cardiac centers with space or staffing constraints.
“With this clearance, we are ready to begin the next chapter of cardiovascular care in the United States,” Pression Chief Executive Officer Adam Salamon said when the FDA clearance was disclosed in January.
The expansion gives Pression additional room for device assembly, testing, inventory, and quality-assurance work as production increases. It also concentrates final manufacturing operations in Coatesville while directing component work to regional suppliers.
Pression was founded by Salamon, a former Lockheed Martin chief scientist. The company developed Wave PRO after completing its WaveCREST clinical trial and advancing the device through the FDA 510(k) process.
The company has received early funding that included investments through Ben Franklin Technology Partners and state-supported venture programs.
With the first commercial unit now in the field, Pression’s next phase centers on converting regulatory clearance and years of product development into customer adoption and recurring manufacturing activity in Chester County.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.